Daewoong goes beyond treatment to transform patients’ lives
VISION
We improve quality of life through
high-quality medicinesOUR GOAL
We are growing into a global pharmaceutical company through
open collaboration
R&D Competitiveness
Advancing Beyond Korea to Lead Global Healthcare
*As of December 2025
R&D Areas
Through innovative therapeutics, high-quality biopharmaceuticals,
and next-generation platform technologies,
we deliver better treatment options and enhanced patient convenience
R&D Achievements
Driven by an innovative pipeline and differentiated technological capabilities,
we are generating outcomes recognized across the global market.
- 1961
Launched URSA
- 1987
Received the first genetic
engineering patent in Korea
- 2001
Launched world’s first number 1
biotechnology new drug Easyef
which is developed in Korea
- 2003
Successfully developed Coenzyme Q10
for the second time in the world
- 2014
Launched new compound Olmesartan-Rosuvastatin
drug 'Olostar' in Korea
- 2019
Internally developed botulinum toxin
approved by USFDA, being the first in Asia
- 2019
Launched ‘Olomax’ which simultaneously targeting
high blood pressure and hyperlipidemia
- 2019
URSA 300mg acquired indication for
‘prevention of gallstone after stomach incision’
for the first time in the world
- 2021
V-Olet, an injection to reduce excessive jaw fat
has been released
- 2022
Launched ‘Fexuclue Tablet’,
a new drug for gastroesophageal reflux disease in Korea
- 2023
Launched a new drug ‘Envlo Tab’,
the first made-in-Korea SGLT-2 inhibitor for
diabetes treatment in Korea
- 1961
Launched URSA
- 1987
Received the first genetic
engineering patent in Korea - 2001
Launched world’s first number 1
biotechnology new drug Easyef
which is developed in Korea - 2003
Successfully developed Coenzyme Q10
for the second time in the world - 2014
Launched new compound Olmesartan-Rosuvastatin
drug 'Olostar' in Korea - 2019
Internally developed botulinum toxin
approved by USFDA, being the first in Asia - 2019
Launched ‘Olomax’ which simultaneously targeting
high blood pressure and hyperlipidemia - 2019
URSA 300mg acquired indication for
‘prevention of gallstone after stomach incision’
for the first time in the world - 2021
V-Olet, an injection to reduce excessive jaw fat
has been released - 2022
Launched ‘Fexuclue Tablet’,
a new drug for gastroesophageal reflux disease in Korea - 2023
Launched a new drug ‘Envlo Tab’,
the first made-in-Korea SGLT-2 inhibitor for
diabetes treatment in Korea
R&D Network
We have established an optimal research environment
that accelerates drug development, enhances quality, and strengthens
the foundation for sustainable growth.
Seoul, KoreaDaewoong Magok C&D CenterSynthetic biologics, Formulation platform clusters, etc.
Yongin, Gyeonggi-do, KoreaDaewoong Bio CenterRecombinant proteins, Cell and gene technologies, etc.
Depok, IndonesiaUI BIO TECHNOLOGY &
ANALYTICS RESEARCH CENTERCell therapy, Organoids, Gene editing, etc.
Bogor, IndonesiaIPB Primate Research CenterPrimate research, Training and development
of veterinary professionals, etc.
Yongin, Gyeonggi-do, KoreaDaewoong Life Science Research InstituteInnovative new drugs, Platform technologies,
Healthy aging, etc.
Bandung, IndonesiaITB DDS Research InstituteResearch and development of platform technologies
Depok, IndonesiaUI Biotechnology Research CenterProteins, Analysis of biological samples including cells
Open Collaboration
Our Stage, Your Ideas:
Daewoong’s Unmatched Execution
There is no shortage of innovative ideas. However, partners with the execution capabilities and infrastructure
to transform those ideas into successful global products—from clinical development to commercialization—are rare.
Daewoong goes beyond funding, offering everything needed to turn ideas into reality.
now is the time to partner with Daewoong.